Paritaprevir, ritonavir, ombitasvir, and dasabuvir treatment in renal transplant patients with hepatitis C virus infection.
2-Naphthylamine
Adult
Anilides
/ therapeutic use
Antiviral Agents
/ therapeutic use
Carbamates
/ therapeutic use
Cyclopropanes
Cyclosporine
/ blood
Female
Hepacivirus
Hepatitis C
/ blood
Humans
Kidney Transplantation
/ adverse effects
Lactams, Macrocyclic
Macrocyclic Compounds
/ therapeutic use
Male
Middle Aged
Postoperative Complications
/ blood
Proline
/ analogs & derivatives
Ritonavir
/ therapeutic use
Sulfonamides
/ therapeutic use
Sustained Virologic Response
Tacrolimus
/ blood
Uracil
/ analogs & derivatives
Valine
Journal
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
ISSN: 2148-5607
Titre abrégé: Turk J Gastroenterol
Pays: Turkey
ID NLM: 9515841
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
entrez:
17
8
2019
pubmed:
17
8
2019
medline:
4
3
2020
Statut:
ppublish
Résumé
The Social Security System of our country reimburses only paritaprevir, ritonavir, ombitasvir, and dasabuvir (PrOD) regime in treatment-naive patients with hepatitis C regardless of kidney disease. Most of our renal transplant (RT) recipients were treated with PrOD. The aim of the present study was to investigate the efficacy and safety of PrOD in RT patients with hepatitis C virus (HCV) infection in a single center real-life experience. RT recipients with a post-transplant follow-up of at least 1 year were included in the study. The patients were treated and monitored according to the guidelines. Blood levels of immunosuppressive patients were closely followed up and adjusted. A total of 21 (12 male and nine female) patients were assessed. The age of the patients was 50.8±8.5 years. Ten patients were infected with G1a, 10 patients with G1b, and one patient with G4 HCV. Two patients had compensated cirrhosis. Eighteen patients were treatment-naive, and three were peginterferon+ribavirin-experienced. Sustained virologic response (SVR12) was achieved in all patients. None of the patients discontinued the treatment. Cyclosporine (Csa) and tacrolimus (Tac) doses were reduced to once a day to once a week to maintain the blood level within normal range. The most common adverse effect was anemia in patients receiving ribavirin. Renal functions did not change during the treatment period. In this real-life experience, all of the 21 PrOD-treated RT recipients reached SVR12. Tac or Csa serum levels were maintained within the normal range with close monitoring. PrOD regime can be successfully and safely used in RT recipients with HCV infection with close follow-up.
Sections du résumé
BACKGROUND/AIMS
OBJECTIVE
The Social Security System of our country reimburses only paritaprevir, ritonavir, ombitasvir, and dasabuvir (PrOD) regime in treatment-naive patients with hepatitis C regardless of kidney disease. Most of our renal transplant (RT) recipients were treated with PrOD. The aim of the present study was to investigate the efficacy and safety of PrOD in RT patients with hepatitis C virus (HCV) infection in a single center real-life experience.
MATERIALS AND METHODS
METHODS
RT recipients with a post-transplant follow-up of at least 1 year were included in the study. The patients were treated and monitored according to the guidelines. Blood levels of immunosuppressive patients were closely followed up and adjusted.
RESULTS
RESULTS
A total of 21 (12 male and nine female) patients were assessed. The age of the patients was 50.8±8.5 years. Ten patients were infected with G1a, 10 patients with G1b, and one patient with G4 HCV. Two patients had compensated cirrhosis. Eighteen patients were treatment-naive, and three were peginterferon+ribavirin-experienced. Sustained virologic response (SVR12) was achieved in all patients. None of the patients discontinued the treatment. Cyclosporine (Csa) and tacrolimus (Tac) doses were reduced to once a day to once a week to maintain the blood level within normal range. The most common adverse effect was anemia in patients receiving ribavirin. Renal functions did not change during the treatment period.
CONCLUSION
CONCLUSIONS
In this real-life experience, all of the 21 PrOD-treated RT recipients reached SVR12. Tac or Csa serum levels were maintained within the normal range with close monitoring. PrOD regime can be successfully and safely used in RT recipients with HCV infection with close follow-up.
Identifiants
pubmed: 31418413
doi: 10.5152/tjg.2019.18833
pmc: PMC6699569
doi:
Substances chimiques
Anilides
0
Antiviral Agents
0
Carbamates
0
Cyclopropanes
0
Lactams, Macrocyclic
0
Macrocyclic Compounds
0
Sulfonamides
0
ombitasvir
2302768XJ8
Uracil
56HH86ZVCT
Cyclosporine
83HN0GTJ6D
Proline
9DLQ4CIU6V
2-Naphthylamine
CKR7XL41N4
dasabuvir
DE54EQW8T1
Valine
HG18B9YRS7
Ritonavir
O3J8G9O825
paritaprevir
OU2YM37K86
Tacrolimus
WM0HAQ4WNM
Types de publication
Evaluation Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
695-701Références
Nephrol Dial Transplant. 2002 Jan;17(1):129-33
pubmed: 11773476
Am J Transplant. 2001 Jul;1(2):171-8
pubmed: 12099366
Gastroenterology. 2002 Nov;123(5):1494-9
pubmed: 12404224
J Am Soc Nephrol. 2004 Dec;15(12):3166-74
pubmed: 15579520
Am J Transplant. 2005 Jun;5(6):1452-61
pubmed: 15888054
Transplant Proc. 2006 Mar;38(2):492-5
pubmed: 16549157
Clin Transplant. 2009 Sep-Oct;23(5):723-31
pubmed: 19573091
Transplantation. 2010 Dec 15;90(11):1165-71
pubmed: 20861806
Hepatology. 2015 May;61(5):1485-94
pubmed: 25557906
Am J Transplant. 2016 May;16(5):1474-9
pubmed: 26587971
Am J Transplant. 2016 May;16(5):1588-95
pubmed: 26604182
Transpl Int. 2016 Sep;29(9):999-1007
pubmed: 27203857
PLoS One. 2016 Jul 14;11(7):e0158431
pubmed: 27415632
Transplantation. 2017 Jul;101(7):1704-1710
pubmed: 28009781
J Hepatol. 2017 Apr;66(4):718-723
pubmed: 28039098
Medicine (Baltimore). 2017 Jul;96(30):e7568
pubmed: 28746204
Clin Liver Dis (Hoboken). 2017 Mar 30;9(3):55-59
pubmed: 30992958